



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/088 (10-95)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	10/696,527
Filing Date	10-29-2003
First Named Inventor	XU
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	USAV2001/0092 - US - CNT

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
YC		BUDDE, Jason M. et al., Comparative Study of AMP579 and Adenosine in Inhibition of Neutrophil-mediated Vascular and Myocardial Injury During 24 h of Reperfusion, Cardiovascular Research; Vol. 47; No. 2; August 2000; pp. 295,302,304.	
YC		CLARK, Kenneth L. et al., AMP 579, a Novel Adenosine Agonist for the Treatment of Acute Myocardial Infarction, Cardiovascular Drug Reviews; Vol.18; No.3; 2000; pp. 183-210.	
YC		MERKEL, Linda et al., Pharmacological Characterization of AMP579, a Novel Adenosine A1/A2 Receptor Agonist and Cardioprotective, Drug Development Research; Vol. 45; No. 30; 1998; pp. 30-43.	
YC		McVEY, Matthew J. et al., Cardiovascular Pharmacology of the Adenosine A1/A2 Receptor Agonist AMP 579: Coronary Hemodynamic and Cardioprotective Effects in the Canine Myocardium, Journal of Cardiovascular Pharmacology; Vol. 33; No. 5; May 1999; pp. 703-710.	
YC		SMITS, G.J. et al., Cardioprotective Effects of the Novel Adenosine A1/A2 Receptor Agonist AMP 579 in a Porcine Model of Myocardial Infarction, Journal of Pharmacology and Experimental Therapeutics; Vol. 286; No. 2; August 1998; pp. 611-618.	
YC		SORBERA, L.A. et al., Treatment of Acute Myocardial Infarction Adenosine A1/A2 Agonist, Drugs of the Future; Vol. 25; No. 9; 2000; pp.900-906.	

Examiner Signature	<i>Yong Chong</i>	Date Considered	7/5/05
-----------------------	-------------------	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet

1

of

2

Attorney Docket Number

USAV2001/0092 - US - CNT

**Complete if Known****Application Number**

10/696,527

Filing Date

10-29-2003

**First Named Inventor**

XU

### Group Art Unit

1614

**Examiner Name**

--	--

Attorney Docket

USAV2001/0092 - US - CNT

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

Long Chong

Date Considered

7/5/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.